Clare Lambert1,2, Susana Da Silva3,4, Amanda K Ceniti1,4, Sakina J Rizvi1,4,5,6, George Foussias3,4,6, Sidney H Kennedy1,4,5,6. 1. Arthur Sommer Rotenberg Suicide and Depression Studies Program, St. Michael's Hospital, Toronto, ON, Canada. 2. Royal College of Surgeons in Ireland, School of Medicine, Dublin, Ireland. 3. Centre for Addiction and Mental Health, Toronto, ON, Canada. 4. Institute of Medical Science, University of Toronto, Toronto, ON, Canada. 5. Mental Health and Addiction Service, St. Michael's Hospital, Toronto, ON, Canada. 6. Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Abstract
BACKGROUND: Anhedonia, as a dysregulation of the reward circuit, is present in both Major Depressive Disorder (MDD) and schizophrenia (SZ). AIMS: To elucidate the clinical and neurobiological differences between schizophrenia (SZ) and depression (MDD) in regard to anhedonia, while reconciling the challenges and benefits of assessing anhedonia as a transdiagnostic feature under the Research Domain Criteria (RDoC) framework. METHODS: In this review, we summarize data from publications examining anhedonia or its underlying reward deficits in SZ and MDD. A literature search was conducted in OVID Medline, PsycINFO and EMBASE databases between 2000 and 2017. RESULTS: While certain subgroups share commonalities, there are also important differences. SZ may be characterized by a disorganization, rather than a deficiency, in reward processing and cognitive function, including inappropriate energy expenditure and focus on irrelevant cues. In contrast, MDD has been characterized by deficits in anticipatory pleasure, development of reward associations, and integration of information from past experience. Understanding the roles of neurotransmitters and aberrant brain circuitry is necessary to appreciate differences in reward function in SZ and MDD. CONCLUSION: Anhedonia as a clinical presentation of reward circuit dysregulation is an important and relatively undertreated symptom of both SZ and MDD. In order to improve patient outcomes and quality of life, it is important to consider how anhedonia fits into both diagnoses.
BACKGROUND: Anhedonia, as a dysregulation of the reward circuit, is present in both Major Depressive Disorder (MDD) and schizophrenia (SZ). AIMS: To elucidate the clinical and neurobiological differences between schizophrenia (SZ) and depression (MDD) in regard to anhedonia, while reconciling the challenges and benefits of assessing anhedonia as a transdiagnostic feature under the Research Domain Criteria (RDoC) framework. METHODS: In this review, we summarize data from publications examining anhedonia or its underlying reward deficits in SZ and MDD. A literature search was conducted in OVID Medline, PsycINFO and EMBASE databases between 2000 and 2017. RESULTS: While certain subgroups share commonalities, there are also important differences. SZ may be characterized by a disorganization, rather than a deficiency, in reward processing and cognitive function, including inappropriate energy expenditure and focus on irrelevant cues. In contrast, MDD has been characterized by deficits in anticipatory pleasure, development of reward associations, and integration of information from past experience. Understanding the roles of neurotransmitters and aberrant brain circuitry is necessary to appreciate differences in reward function in SZ and MDD. CONCLUSION: Anhedonia as a clinical presentation of reward circuit dysregulation is an important and relatively undertreated symptom of both SZ and MDD. In order to improve patient outcomes and quality of life, it is important to consider how anhedonia fits into both diagnoses.
Authors: Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao Journal: N Engl J Med Date: 2005-09-19 Impact factor: 91.245
Authors: Richard S E Keefe; Robert M Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman Journal: Arch Gen Psychiatry Date: 2007-06
Authors: G K Murray; P R Corlett; L Clark; M Pessiglione; A D Blackwell; G Honey; P B Jones; E T Bullmore; T W Robbins; P C Fletcher Journal: Mol Psychiatry Date: 2007-08-07 Impact factor: 15.992
Authors: Negar Fani; Vasiliki Michopoulos; Sanne J H van Rooij; Cherita Clendinen; Raven A Hardy; Tanja Jovanovic; Barbara O Rothbaum; Kerry J Ressler; Jennifer S Stevens Journal: J Psychiatr Res Date: 2019-05-14 Impact factor: 4.791
Authors: Paul J Silvia; Kari M Eddington; Kathleen H Maloney; Jaimie M Lunsford; Kelly L Harper; Thomas R Kwapil Journal: Pers Individ Dif Date: 2021-04-30